Literature DB >> 30293213

Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.

Sergio Pedraza-Arévalo1,2,3,4,5, Manuel D Gahete1,2,3,4,5, Emilia Alors-Pérez1,2,3,4,5, Raúl M Luque6,7,8,9,10, Justo P Castaño11,12,13,14,15.   

Abstract

Neuroendocrine tumors (NETs) comprise a complex and highly heterogeneous group of neoplasms that can arise all over the body, originating from neuroendocrine cells. NETs are characterized by a general lack of symptoms until they are in advanced phase, and early biomarkers are not as available and useful as required. Heterogeneity is an intrinsic, pivotal feature of NETs that derives from diverse causes and ultimately shapes tumor fate. The different layers that conform NET heterogeneity include a wide range of distinct characteristics, from the mere location of the tumor to its clinical and functional features, and from its cellular properties, to the core signaling and (epi)genetic components defining the molecular signature of the tumor. The importance of this heterogeneity resides in that it translates into a high variability among tumors and, hence, patients, which hinders a more precise diagnosis and prognosis and more efficacious treatment of these diseases. In this review, we highlight the significance of this heterogeneity as an intrinsic hallmark of NETs, its repercussion on clinical approaches and tumor management, and some of the possible factors associated to such heterogeneity, including epigenetic and genetic elements, post-transcriptional regulation, or splicing alterations. Notwithstanding, heterogeneity can also represent a valuable and actionable feature, towards improving medical approaches based on personalized medicine. We conclude that NETs can no longer be viewed as a single disease entity and that their diagnosis, prognosis and treatment must reflect and incorporate this heterogeneity.

Entities:  

Keywords:  Cancer; Carcinoid; Complexity; Hallmark; Heterogeneity; Neuroendocrine tumors

Mesh:

Year:  2018        PMID: 30293213     DOI: 10.1007/s11154-018-9465-0

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  158 in total

Review 1.  Sunitinib in pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Pascal Hammel; Chantal Dreyer; Christian Maatescu; Olivia Hentic; Philippe Ruszniewski; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-06-02       Impact factor: 4.493

2.  The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.

Authors:  Seong-Jang Kim; Kyoungjune Pak; Phillip J Koo; Jennifer J Kwak; Samuel Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-09       Impact factor: 9.236

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 4.  Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1.

Authors:  Koen M A Dreijerink; H T Marc Timmers; Myles Brown
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

Review 5.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

6.  Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Authors:  Noriaki Sunaga; David S Shames; Luc Girard; Michael Peyton; Jill E Larsen; Hisao Imai; Junichi Soh; Mitsuo Sato; Noriko Yanagitani; Kyoichi Kaira; Yang Xie; Adi F Gazdar; Masatomo Mori; John D Minna
Journal:  Mol Cancer Ther       Date:  2011-02       Impact factor: 6.261

7.  RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed?

Authors:  Volker F H Brauer; Gerhard H Scholz; Susanne Neumann; Tobias Lohmann; Ralf Paschke; Christian A Koch
Journal:  Endocr Pract       Date:  2004 Jan-Feb       Impact factor: 3.443

Review 8.  Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.

Authors:  Georgios K Dimitriadis; Martin O Weickert; Harpal S Randeva; Gregory Kaltsas; Ashley Grossman
Journal:  Endocr Relat Cancer       Date:  2016-07-26       Impact factor: 5.678

9.  Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.

Authors:  Jarosław B Ćwikła; Lisa Bodei; Agnieszka Kolasinska-Ćwikła; Artur Sankowski; Irvin M Modlin; Mark Kidd
Journal:  J Clin Endocrinol Metab       Date:  2015-09-08       Impact factor: 5.958

Review 10.  Targeting the mTOR signaling pathway in neuroendocrine tumors.

Authors:  Jennifer Chan; Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2014-09
View more
  10 in total

Review 1.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

2.  Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic steps.

Authors:  Christian A Koch; S Petersenn
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

3.  Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length.

Authors:  Francesco Cocchiara; Claudia Campana; Federica Nista; Giuliana Corica; Marco Ceraudo; Angelo Milioto; Diego Criminelli Rossi; Gianluigi Zona; Diego Ferone; Federico Gatto
Journal:  Pituitary       Date:  2021-11-10       Impact factor: 4.107

4.  Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.

Authors:  Joan Gil; Montserrat Marques-Pamies; Elena Valassi; Araceli García-Martínez; Guillermo Serra; Cristina Hostalot; Carmen Fajardo-Montañana; Cristina Carrato; Ignacio Bernabeu; Mónica Marazuela; Helena Rodríguez-Lloveras; Rosa Cámara; Isabel Salinas; Cristina Lamas; Betina Biagetti; Andreu Simó-Servat; Susan M Webb; Antonio Picó; Mireia Jordà; Manel Puig-Domingo
Journal:  Biomedicines       Date:  2022-02-16

5.  Data mining analyses for precision medicine in acromegaly: a proof of concept.

Authors:  Joan Gil; Montserrat Marques-Pamies; Miguel Sampedro; Susan M Webb; Guillermo Serra; Isabel Salinas; Alberto Blanco; Elena Valassi; Cristina Carrato; Antonio Picó; Araceli García-Martínez; Luciana Martel-Duguech; Teresa Sardon; Andreu Simó-Servat; Betina Biagetti; Carles Villabona; Rosa Cámara; Carmen Fajardo-Montañana; Cristina Álvarez-Escolá; Cristina Lamas; Clara V Alvarez; Ignacio Bernabéu; Mónica Marazuela; Mireia Jordà; Manel Puig-Domingo
Journal:  Sci Rep       Date:  2022-05-28       Impact factor: 4.996

6.  NETest: serial liquid biopsies in gastroenteropancreatic NET surveillance.

Authors:  Mark J C van Treijen; Catharina M Korse; Wieke H Verbeek; Margot E T Tesselaar; Gerlof D Valk
Journal:  Endocr Connect       Date:  2022-09-07       Impact factor: 3.221

7.  Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.

Authors:  Vikas Prasad; Raj Srirajaskanthan; Christos Toumpanakis; Chiara Maria Grana; Sergio Baldari; Tahir Shah; Angela Lamarca; Frédéric Courbon; Klemens Scheidhauer; Eric Baudin; Xuan-Mai Truong Thanh; Aude Houchard; Clarisse Dromain; Lisa Bodei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-15       Impact factor: 9.236

8.  Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.

Authors:  Wu-Hu Zhang; Xuan Han; He-Li Gao; Wen-Quan Wang; Shuai-Shuai Xu; Shuo Li; Tian-Jiao Li; Hua-Xiang Xu; Hao Li; Long-Yun Ye; Xuan Lin; Chun-Tao Wu; Jiang Long; Xian-Jun Yu; Liang Liu
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

Review 9.  Pasireotide in the Personalized Treatment of Acromegaly.

Authors:  Manel Puig-Domingo; Ignacio Bernabéu; Antonio Picó; Betina Biagetti; Joan Gil; Cristina Alvarez-Escolá; Mireia Jordà; Montserrat Marques-Pamies; Berta Soldevila; María-Angeles Gálvez; Rosa Cámara; Javier Aller; Cristina Lamas; Mónica Marazuela
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555

10.  Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors.

Authors:  Sergio Pedraza-Arevalo; Alejandro Ibáñez-Costa; Ricardo Blázquez-Encinas; Miguel R Branco; Mari C Vázquez-Borrego; Aura D Herrera-Martínez; Eva Venegas-Moreno; Raquel Serrano-Blanch; Álvaro Arjona-Sánchez; María A Gálvez-Moreno; Marta Korbonits; Alfonso Soto-Moreno; Manuel D Gahete; Marika Charalambous; Raúl M Luque; Justo P Castaño
Journal:  Mol Oncol       Date:  2021-10-26       Impact factor: 6.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.